The FDA has granted accelerated approval to Modeyso (dordaviprone) for the treatment of diffuse midline glioma harboring an ...

The FDA granted accelerated approval to dordaviprone (Modeyso) as the first systemic therapy for adults and children with ...

Modeyso is the first and only treatment option approved by the FDA for this ultra-rare and aggressive brain tumor that affects an estimated 2,000 people in the U.S. each year, many of whom are ...

In a combined analysis of patients from five open-label trials, 22 percent responded to the protease activator, the first approved treatment for the rare disease.